Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Braiteh
Fadi
F
Department of Investigational Cancer Therapeutics, Phase I Program, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Kurzrock
Razelle
R
Johnson
Faye M
FM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D044963:Biopsy, Fine-Needle; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005140:Eyelashes / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment
D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors